Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for Neonates
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
CeriBell (NASDAQ:CBLL) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $17.00. They now have an "overweight" rating on the stock.
CeriBell (NASDAQ:CBLL) had its price target lowered by analysts at TD Cowen from $36.00 to $20.00. They now have a "buy" rating on the stock.